Stock Pulse
Elevance Health (ELV) demonstrated strong Q4 2024 revenue growth driven by premium yields and acquisitions, with analysts raising price targets and maintaining buy ratings [2]. The company's ROE exceeds industry averages and is projected to grow further [1], and its strong financial health is supported by a net cash position and substantial free cash flow [5]. While full-year EPS slightly missed guidance [7] and ROCE growth has been stagnant [8], the stock price rebounded due to perceived undervaluation [3] and investor interest in defensive sectors [10]. Future growth prospects depend on earnings momentum [9], operational improvements [7], and effective capital allocation [8], with some analysts suggesting higher potential returns from other sectors like AI [2], [3].